Keeling Peter
Diaceutics, 727 Antrim Road, Belfast, BT154EJ, UK.
Per Med. 2007 Feb;4(1):73-81. doi: 10.2217/17410541.4.1.73.
This perspective biases on the side that personalized medicine can contribute to a more efficient collective model; however, the hard economics need and deserve significantly more critical analysis and new data input than they are currently being given, to determine their role, or not, in driving change. Put simply, as with the birth of all new and promising developments in healthcare, myth, hope and trend-spotting are driving this market forward, rather than any hard evidence of a sustainable commercial business model for all stakeholders. While there are clear economic benefits to aspects of delivery along the way to personalized care, there may in fact be no compelling economic drivers for radical change for payers and the pharmaceutical industry. The best they can hope to achieve is that the balance sheet is, just that, in balance.
这种观点偏向于认为个性化医疗有助于形成更高效的集体模式；然而，与目前所得到的相比，其艰难的经济学需求需要且理应得到更深入的批判性分析和新的数据输入，以确定它们在推动变革方面的作用（或没有作用）。简而言之，就像医疗保健领域所有新的、有前景的发展诞生时一样，神话、希望和趋势观察正在推动这个市场前进，而不是有任何确凿证据表明存在一个对所有利益相关者都可持续的商业模式。虽然在走向个性化医疗的过程中，某些方面的交付有明显的经济效益，但实际上对于支付方和制药行业来说，可能没有令人信服的经济驱动力来推动根本性变革。他们最希望实现的是资产负债表保持平衡。
